# Title: B cell depletion attenuates CD27 signaling of T helper cells in multiple

2 sclerosis

1

- 3 **Authors:** Can Ulutekin<sup>1,†</sup>, Edoardo Galli<sup>1,2,†</sup>, Mohsen Khademi<sup>3</sup>, Ilaria Callegari<sup>2</sup>, Fredrik Piehl<sup>3</sup>,
- 4 Nicholas Sanderson<sup>2</sup>, Massimo Filippi<sup>4</sup>, Roberto Furlan<sup>4</sup>, Tomas Olsson<sup>3</sup>, Tobias Derfuss<sup>2</sup>, Florian
- 5 Ingelfinger<sup>1,‡</sup> & Burkhard Becher<sup>1,‡</sup>,\*
- 6 Affiliations:
- <sup>1</sup>Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
- 8 <sup>2</sup>Department of Biomedicine, University Hospital Basel; Basel, Switzerland.
- <sup>3</sup>Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet; Stockholm,
- 10 Sweden.

16

- <sup>4</sup>Clinical Neuroimmunology Unit, Institute of Experimental Neurology, Division of Neuroscience,
- 12 San Raffaele Scientific Institute; Milan, Italy.
- <sup>†</sup> These authors contributed equally.
- <sup>‡</sup> These authors contributed equally.
- \* Correspondence to: <u>becher@immunology.uzh.ch</u>
- One Sentence Summary: B cell depletion contracts follicular T helper cells, displaces memory-
- to-naïve ratio and impairs CD27 signaling in T helper cells.
- 19 **Abstract:** Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
- 20 (CNS). Traditionally, MS was held to be a T-cell mediated disease, but accumulating evidence
- during the last decade also highlighted the crucial importance of B cells for the disease progression.
- 22 Particularly, B cell depleting therapies (BCDTs), have demonstrated striking efficacy in
- 23 suppressing inflammatory disease activity in relapsing-remitting MS. However, a detailed
- 24 understanding of the role of B cells in the pathogenesis of MS is still lacking, and by extension
- 25 also the mechanism of action of BCDTs. In this longitudinal multi-center study, we investigated
- 26 the impact of BCDTs on the immune landscape in MS patients using high-dimensional single-cell
- 27 immunophenotyping (cytometry by time-of-flight; CyTOF). Algorithm-guided analyses revealed
- 28 phenotypic changes in the newly reconstituted B cell compartment after BCDT, as well as a
- 29 marked specific reduction of circulating T follicular helper (Tfh) cells with a concomitant
- 30 upregulation of CD27 surface expression in memory T helper cells and Tfh cells. These findings
- indicate a costimulatory mechanism in the CD27/CD70 signaling pathway, through which B cells
- 32 sustain the activation of pathogenic T cells. Disrupting the CD27/CD70 signaling axis via BCDTs
- provides a potential explanation for its clinical efficacy.

#### **Main Text:**

34

35

58 59

60

61

62

63

64

65

66 67

68 69 70

71

### INTRODUCTION

MS is an immune-mediated disease, characterized by demyelination of the CNS, where disease 36 progression results from a complex interplay between partially understood neurodegenerative 37 38 processes and inflammatory episodes. Traditionally, MS was considered a T cell-mediated disease 39 based on evidence inferred from animal models of neuroinflammation (1, 2). However, therapies targeting exclusively T lymphocytes in patients demonstrated only weak clinical efficacy (3). More 40 recent evidence supported the involvement of B cells in the disease pathogenesis and progression 41 of MS. One of the most convincing findings highlighting the critical role of B cells in the disease 42 has been the high response rate of BCDTs in ameliorating MS (4-6). These findings have shifted 43 44 the perception of the disease towards mechanisms in which the interplay between B and T cells

45 takes a more prominent role (7).

46 Despite the impressive clinical efficacy of BCDTs in suppressing inflammatory disease activity in MS, their precise mechanism of action remains unclear and is an area of active research (8). 47 Removal of the total circulating immunoglobulin fraction via plasmapheresis (9, 10), or interfering 48 49 with potentially pathogenic antibodies via intravenous immune globulin (IVIG) injections (11–13) have shown limited efficacy. Furthermore, anti-CD20-mediated BCDTs do not target plasma cells 50 and have minimal effects on antibody titters (6). Thus, it appears likely that the success of BCDTs 51 52 depends on B-cell activities other than antibody production, such as cytokine secretion, antigen presentation or co-stimulation. Several studies report upregulation of proinflammatory cytokines 53 54 and a concomitant downregulation of immunoregulatory cytokines in B cells of MS (14-20). Apart from cytokine production, B cells are antigen-presenting cells (APCs) and can efficiently prime T 55 cells (21). Accordingly, polymorphisms in major histocompatibility complex (MHC) genes 56 demonstrate the strongest association with MS susceptibility, particularly those encoding for class 57 II MHC molecules (22-25).

The characterization of the replenished B cell population after depletion with BCDTs has been examined before (14, 16, 19), but studies investigating the immune compartment as a whole are missing. Here, we systematically investigated the effects of BCDTs on the peripheral immune landscape in MS patients. We used high-dimensional mass cytometry in conjunction with unsupervised clustering to analyze the systemic immune compartment of MS patients after BCDTs in a longitudinal manner. B cell depletion evoked alterations in CD4<sup>+</sup> T cell composition and expression of costimulatory molecules suggesting that the cell-to-cell interactions between B and T cells play a key role during MS immunopathology that could be compromised using BCDTs. Our study thereby addresses the enigmatic role of B cells in MS pathology and suggests a costimulatory mechanism of action for B cell depleting agents in MS patients.

### **RESULTS**

#### The replenished B cell compartment is phenotypically altered in MS

- 72 To characterize the immune landscape of MS patients after BCDT, we collected longitudinal
- peripheral blood mononuclear cell (PBMC) samples of MS patients undergoing BCDT (table 1).
  The samples were analyzed by two partially overlapping mass cytometry panels in order to deeply
- 74 The samples were analyzed by two partially overlapping mass cytometry panels in order to deeply 75 interrogate cellular states and subsets associated with the clinical success of BCDT.
- 75 Interrogate cellular states and subsets associated with the clinical success of BCD1.
- 76 Dimensionality reduction using Uniform Manifold Approximation and Projection (UMAP) and

unsupervised FlowSOM clustering identified B cells, CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, regulatory T (Treg) cells, γδ T cells, natural killer (NK) cells and myeloid cells (fig. 1, A and B).

 $\begin{array}{c} 101 \\ 102 \end{array}$ 

To assess the kinetics of the impact of BCDTs on discrete B cell subsets, B cells were dissected into canonical B cell subsets: memory, naïve, marginal zone-like (MZ-like), and plasmablasts (fig.1C, and fig. S1A). In line with previous reports (26), each of the investigated B cell subsets were efficiently depleted after treatment infusions (fig. 1D). To assess how the newly repopulating B cell compartment differed following BCDT, we compared the B cell compartment before therapy initiation to timepoints, where a replenishment could be observed (8-45 weeks since last infusion, median 22; 106-7041 cell counts, median 399). Consistent with previous reports (27) we observed a decrease in the frequency of memory B cells and an increase in the frequency of naïve B cells (fig. 1E).

Newly replenished B cells revealed a downregulation of CCR7, the chemokine receptor essential for migration to lymphoid tissues (28) and CD268 and CD19 (fig. 1F and fig. S1B). CD268, encoding for the B-cell-activating receptor (BAFF-R), is a crucial regulator of B- and T-cell activity (29), however, failing evaluation as a pharmacological target in MS (30), in spite of compelling evidence from preclinical studies (31, 32). CD19 is a critical protein of the CD19 complex, involved in the amplification of B cell receptor signaling and subsequent B cell activation (33, 34).




Fig. 1. BCDTs deplete B cells efficiently and alter the B cell phenotype after reconstitution. (A) UMAP of 52,500 cells randomly sampled from the combined dataset. The number of sampled cells was constant across samples. Color code indicates the main clusters generated through clustering and manual annotation. (B) Heatmap showing the median marker expression across the identified main clusters. (C) Heatmap shows the median marker expression across the identified B cell sub-clusters. (D) Frequency of B cell subsets among total cells across time after infusion. Points represent individual samples. The line represents the conditional mean of B cell subset frequency. (E) Pie chart showing the composition of distinct subsets within the B cell compartment before (left) and after (right) treatment.

- The after-treatment B cell compartment consists of late timepoint representing the replenishing B cell compartment.
- 104 (F) Bar plot displaying changes in marker expression of newly populating B cells in MS. Marker expression changes
- visualized through paired Wilcoxon effect size. Color code indicates up- or downregulation.

## B cell depletion reduces the frequency of T follicular helper cells in MS patients

- To have a broad overview of the impact of BCDTs on the immune compartment, we investigated
- the frequency of distinct immune cell populations in MS patients before and after therapy. To
- account for the bias elicited by the depletion of B cells, we computationally removed them from
- our analysis and normalized the frequencies accordingly. We observed that the canonical immune
- 112 cell populations were not altered by BCDT treatment suggesting a more nuanced effect of the
- treatment on the immune landscape (fig. S1C).

106

107

133

134


- B- and T-cell interactions have a fundamental role during the immunopathology of MS (35), and
- interference with these interactions could partially account for the clinical efficacy of BCDTs. To
- better characterize the impact of BCDTs on the T cell compartment we defined five distinct CD4<sup>+</sup>
- T cell subsets in the peripheral blood of MS patients; central memory, effector memory, naïve, T
- follicular helper (Tfh) and CD103<sup>+</sup> cells (fig. 2A). For each subset we longitudinally analyzed the
- shift in the frequency after BCDT (fig. 2B). We observed a significant decrease in the frequency
- of Tfh cells in response to BCDT treatment. Circulating Tfh cells have been reported to be
- increased in the blood of MS patients and a reduction of these has been associated with a remission
- of the disease (36, 37). These observations suggest that BCDTs may indirectly deplete potentially
- pathogenic Tfh cells and highlight the interdependence of these with B cells. Consistent with
- previous observations (38), when comparing changes in the naïve-to-memory ratio, we observed a
- shift from memory towards naïve Th cells (fig. 2C).
- Analogous, to the CD4<sup>+</sup> T cell compartment, we defined distinct subsets within the CD8<sup>+</sup> T cell
- compartment (fig. S2A). Analyzing the shift in the frequency of these subsets in BCDT treated
- MS patients, we observed that these were largely unaffected in response to BCDT treatment (fig.
- 129 S2B). Accordingly, the ratio of naïve-to-memory cytotoxic T cells was unchanged between
- untreated and treated MS (fig. S2C). Despite the dominance of CD8<sup>+</sup> T cells over CD4<sup>+</sup> T cells in
- lesions of MS patients and their potential involvement in the immunopathology of MS (39–41),
- these results point towards a highly selective influence of BCDTs on the Th cell compartment.

#### B cell depletion leads to selective increase in CD27 expression across memory Th cell subsets

- Next, we assessed whether phenotypic alterations in CD4<sup>+</sup> T cell subsets could be associated with
- BCDTs. To this end, we assigned each marker to one of three distinct, mutually exclusive groups:
- surface activation markers, surface localization markers and cytokines. For each subset we
- compared longitudinally how the expression levels changed in response to B cell depletion (fig.
- 2D). This approach revealed a selective disparity in CD27 expression across T helper (Th) cell
- 139 2D). This approach revealed a selective disparity in CD2/ expression across 1 helper (111) cen
- subsets, where we observed increased surface CD27 across central and effector memory Th cells
- as well as Tfh cells (fig. 2, E and F). In relation to our observations, soluble CD27 (sCD27) in the
- cerebrospinal fluid (CSF) is a prognostic biomarker in MS and its protein levels correlate directly
- with disease severity (42–44).
- The costimulatory molecule CD27 is part of the tumor necrosis factor receptor superfamily
- (TNFRSF) and its ligand CD70 is expressed by APCs (45–48). CD27 signaling leads to the

induction of pro-survival pathways (49, 50) and supports the efficient expansion and differentiation 146 147 of activated T cells (51-54). CD27 expression is transiently upregulated upon TCR-engagement (55–57) and proteolytically cleaved and released as soluble CD27 (sCD27) upon sustained signaling 148 149 (42, 58, 59). Surface expression of CD27 therefore naturally declines along the T cell differentiation path (47), with naïve T cells having the highest expression and more differentiated subsets showing 150 a lower expression. Thus, higher surface CD27 expression levels may be a result of impaired 151 interaction due to the depletion of CD70 expressing B cells and could represent an attenuation of 152 CD27 signaling. Indeed, when we examined surface CD27 levels along the differentiation path of 153 Th cells we observed an overall increased expression after BCDT (fig. 2G). This effect was most 154 pronounced in more differentiated Th cells (fig. 2H). In summary, elevated surface levels of CD27 155 is likely the consequence of decreased engagement with CD70 on B cells, which could partially 156 hamper the pathogenic potential of Th cells. 157

Next, we assessed changes in marker expression in the CD8<sup>+</sup> T cell compartment analogous to the previous analysis for the CD4<sup>+</sup> T cells. None of the analyzed markers appeared dysregulated after BCDT in the cytotoxic T cell compartment (fig. S2D). Specifically, CD27 expression levels during cytotoxic T cell differentiation followed a similar expression pattern as observed for the CD4<sup>+</sup> T cell counterpart but did not reveal any changes as a result of BCDT, again highlighting the selectivity of BCDT on Th cell compartment (fig. S2, E and F).



**Fig. 2. BCDTs alter the peripheral CD4**<sup>+</sup> **T cell landscape of MS patients.** (**A**) Heatmap showing median expression of lineage markers across identified CD4+ T cell subsets. (**B**) Violin plots showing changes in the frequency across CD4+ T cell subsets in BCDT treated MS. Paired Wilcoxon rank-sum test and Benjamini-Hochberg correction was applied. (**C**) Violin plots showing changes in the naive to memory ratio within the CD4+ T cell compartment. Paired Wilcoxon rank-sum test was applied. (**D**) Radar plots showing changes in the marker expression of CD4+ T cell subsets in BCDT treated MS. Values correspond to -log10(p-value) and were adjusted with the Benjamini-Hochberg correction. Inner circle color annotations denote each respective subset. Bar color denotes the upregulation or downregulation of the respective marker. Marker order is consistent across subsets. (**E**) Various heatmaps showing CD27 expression of each MS patient before and after B cell depleting treatment. Each heatmap denotes a different CD4+ T cell subset. CD27 expression on each heatmap normalized by transforming the range of expression to maximal separation within 0 and 1 values. (**F**) Violin plots showing changes in CD27 expression across CD4+ T cell subsets in BCDT treated MS. P values correspond to the paired Wilcoxon rank-sum test applying a Benjamini-Hochberg correction. (**G**) Median CD27 expression along CD4<sup>+</sup> T cell subsets of the MS patients. Points

are individual sample values. Color code denotes patient values before or after treatment. (H) Percent fold-change in 178 179

CD27 expression along CD4<sup>+</sup> T cell subsets of the MS patients, depicted in percent changes. Shaded area represents

the 95 % confidence interval.

180

181

182 183

184

185

186

187

188

189

190

191

192 193

194

195 196

197

198

199

200

201

202

203

204

205


206

## Analysis of independent cohort confirmed the impact of BCDTs on circulatory Tfh and CD27 expression

Next, we investigated whether the selective changes of BCDT on the Th cell compartment could be validated in an independent cohort derived from a distinct clinical center (table 2). This confirmed the reduction of circulating Tfh cells in response to BCDTs in an additional dataset (fig. 3A). When analyzing changes in CD27 expression across CD4<sup>+</sup> memory T cell and Tfh cell subsets, we confirmed our previous result and observed significant upregulation in surface CD27 levels in central memory T cells and Tfh cells but not effector memory T cells (fig. 3B). In conclusion, using an independent cohort of BCDT treated MS patients, we confirmed our findings that Tfh cells specifically decrease in frequency and surface CD27 levels of central memory T cells and Tfh cells increase after treatment.

## BCDT in myasthenia gravis patients induced CD27 expression in Tfh cells

To assess whether the selective influence of BCDTs on the Th cell compartment was specific to MS pathophysiology or a universal feature of BCDTs. We next analyzed the influence of BCDTs on the CD4<sup>+</sup> T cell compartment in myasthenia gravis (MG) patients in an independent cohort (table 3). For comparative purposes, these patients were selected to be treatment naïve to immune suppressants, except for exposure to low to moderate doses of corticosteroids in some cases. Longitudinal comparison of Tfh cell frequencies revealed a decreasing trend that did not reach statistical significance (fig. 3C). Similarly, we evaluated surface CD27 levels in memory T cells and Tfh cells in response to BCDTs. Consistent with the MS findings, we observed a trend towards upregulation (fig. 3D). However only in Tfh cells this measurement reached statistical significance. The number of MG patients analyzed here is relatively small, thus limiting the statistical power. Despite the disparity in clinical efficacy of BCDTs in MS and MG (60, 61), we can conclude that upregulation of CD27 in Tfh cells is a universal hallmark of the therapy.



**Fig. 3.** The altered CD4<sup>+</sup> T cell landscape is consistent across cohorts. (A) Violin plot showing the frequency in CD4<sup>+</sup> Tfh cells in B cell depleted MS patients of the validation cohort. Paired Wilcoxon rank-sum test was applied. (B) Violin plots showing changes in CD27 expression across CD4<sup>+</sup> memory and Tfh cells in B cell depleted MS patients of the validation cohort. Paired Wilcoxon rank-sum test was applied. (C) Violin plot showing the frequency in CD4<sup>+</sup> Tfh cells in B cell depleted MG patients of the validation cohort. Paired Wilcoxon rank-sum test was applied. (D) Violin plots showing changes in CD27 expression across CD4<sup>+</sup> memory and Tfh cells in B cell depleted MG patients of the validation cohort. Paired Wilcoxon rank-sum test was applied.

### **DISCUSSION**

BCDT is one of the most impactful therapeutic advancements for the treatment of MS to date (7). Nevertheless, the mechanism by which BCDTs mediate their clinical efficacy remains entirely unknown. As mentioned above, the cardinal feature of B cells, namely the production of antibodies cannot be responsible for the effect in MS. Nevertheless, it is surprising that the effect that BCDT has on disease development has not yet been revealed. Here, we sought to provide an unbiased roadmap of the systemic immune compartment in response to the elimination of B cells. Given that B cell depletion eliminates 5 to 10 % of lymphocytes from the PBMC compartment, the subtlety of the consequences for the remaining immune compartment is surprising. To better understand how BCDT alters the non-B-cell immune compartment, we designed an immunophenotyping protocol combined with a comprehensive algorithm-guided analysis.

Here, we demonstrated a selective influence of BCDTs on the CD4<sup>+</sup> T cell compartment in the peripheral blood of MS patients. We observed an upregulation of surface CD27 levels along the Th cell differentiation path in response to BCDTs, that was most pronounced in memory Th cells and Tfh cells. Upon sustained signaling CD27 is cleaved into its soluble form. Therefore its

- upregulation in response to BCDT could be indicative of an attenuation of the CD27/CD70
- signaling pathway. It is conceivable that dysregulated interactions between B and Th cells act as
- 233 drivers of MS and depletion of B cells could impair these interactions. In parallel to its impairment
- upon BCDTs, loss of surface CD27 molecules in T cells is a molecular feature of terminal
- differentiation (56, 62). The BCDT induced upregulation of surface CD27 may imply an
- 236 impediment in the activity of Th cells, partially explaining the efficacy of the therapies.
- In line with this hypothesis, increased levels of sCD27 in the CSF is a well-established biomarker
- of MS (42) and has been positively correlated to relapse rates (63). Furthermore, sCD27 in the CSF
- of MS patients was highly predictive of active intrathecal inflammation (43). Reduced sCD27
- levels in the CSF has been reported in response to common therapies in MS, including BCDTs
- 241 (64–66). Additional support of the involvement of the CD27/CD70 pathway in MS comes from
- studies using preclinical models of MS. It was shown that administration of anti-CD70 monoclonal
- 243 antibody significantly repressed experimental autoimmune encephalomyelitis (EAE) and Theiler's
- murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) and resulted in the
- reduction of clinical scores as well as inflammation and demyelination levels (67, 68). Similarly, in
- 246 a transgenic mouse, where the T-cell receptor recognizes the myelin oligodendrocyte glycoprotein,
- constitutive CD70 expression on B cells increased susceptibility of mice towards spontaneous
- EAE development (69).
- In addition to a dysregulation in the B cell/T cell interface via the CD27/CD70 axis, we observed
- a significant decrease in the frequency of Tfh cells in MS patients, after treatment with BCDTs.
- 251 Given the central role of Tfh cells in providing costimulatory maturation and proliferation signals
- 252 to B cells, their decrease in frequency after depletion of B cells highlights the importance of direct
- cell-cell interactions during the immunopathology of MS. Numerous studies underscore the
- importance of Tfh cells in MS pathophysiology (36, 37, 70). CXCL13, a chemokine involved in the
- 255 migration of B cells and Tfh cells (71, 72), is found to be elevated in the CSF of MS patients (73)
- and predictive of a more severe disease course (74). Furthermore, rituximab treatment has been
- shown to decrease CXCL13 as well as T cells in the CSF, in a proportional manner (75). CXCL13
- is prominently produced by actively demyelinating lesions but not by chronic inactive lesions (76–
- 259 78). Finally, increased levels of circulating Tfh cells have been reported in MS and found to be
- reduced in patients with complete remission (36, 37).
- In conclusion, our study highlights a highly selective influence of BCDTs on the Th cell
- compartment of MS patients. These findings suggest that BCDTs may cause a partial blockade in
- 263 the full effector differentiation of Th cells due to compromised CD27/CD70 signaling.
- 264 Furthermore, our analysis reports a significant reduction in the frequency of Tfh cells and
- emphasizes their involvement in MS as suggested by others. Our study thereby identifies a
- 266 potential mechanism of action for BCDTs and reveals important insights into the pathophysiology
- 267 of MS.
- 268 It was vital for this study, to include patients treated with BCDT and to obtain samples prior as
- well as after the treatment induction. This fact is mainly responsible for the relatively limited
- sample size and therefore limited statistical power. Nevertheless, our findings could be validated
- in patient cohorts obtained from two independent clinical centers. Current untargeted single-cell
- technologies (e.g. RNA-seq) are limited in their throughput and resolution, but they could have
- potentially revealed additional alterations driven by BCDT. As a compromise here we used
- 274 CyTOF, which allowed for a combined analysis of multiple barcoded patient samples. Even though
- 275 the dynamic range for detection of protein expression and reproducibility across the samples is

very good, the quasi-targeted nature of CyTOF may create a bias. Finally, this study would have benefitted from access to longitudinal CSF samples, which likely are more reflective of the events that occur within inflammatory CNS lesions.

#### MATERIALS AND METHODS

### Study design

The objective of this study was to investigate the immune landscape of MS patients in response to BCDTs. For this purpose longitudinal samples, before and after therapy induction, were analyzed via CyTOF. Two overlapping mass cytometry panels were applied interrogating various costimulatory and trafficking molecules, cytokines, and lineage markers. Data was acquired in two independent runs and normalized through batch correction. A computational pipeline comprising clustering, dimensionality reduction and statistical analyses was employed in order to retrieve phenotypic immune alterations in response to BCDT. Our findings were validated in an independent cohort from a distinct clinical center.

## Longitudinal PBMC samples of MS patients during BCDT in the discovery cohort

For the initial discovery cohort longitudinal PBMC samples of MS patients before and after BCDT were collected at the MS center of the University Hospital Basel (Table 1). MS diagnosis was based on the revised McDonald criteria(79). All patients gave written informed consent, with ethical oversight by the Ethikkommission beider Basel (Ref.Nr. EK: 49/06).

In the discovery cohort samples from multiple timepoints were available. Inclusion criteria for the discovery cohort included longitudinal patient samples, appropriate B cell depletion after BCDTs as well as no previous disruptive treatments. When performing longitudinal statistical analyses, samples from timepoints closest to initial treatment were chosen. Samples containing the highest B cell frequency after treatment were chosen for the analysis of repopulating B cells and a 100-cell cut-off was applied. As such 8 patients out of 12 were qualified.

**Table 1:** Clinical and demographic characteristics of patients in the discovery cohort.

ID	Diagnosis	Age Range	Sex	Treatment	Previous Treatment	Cycle of Treatment	Days Since Last Treatment	Days Since First Treatment
1	RRMS	31 - 40	M	Ocrelizumab	None	2	146	160
2	RRMS	31 - 40	F	Ocrelizumab	None	2	148	162
3	RRMS	21 - 30	M	Ocrelizumab	Interferon β	2	57	71
4	RRMS	21 - 30	F	Ocrelizumab	None	2	43	57
5	PPMS	61 - 70	F	Rituximab	None	6	126	877
6	PPMS	51 - 60	M	Ocrelizumab	None	3	117	320
7	RRMS	41 - 50	F	Ocrelizumab	None	2	43	57
8	RRMS	21 - 30	F	Ocrelizumab	None	2	154	168
9	RRMS	31 - 40	F	Ocrelizumab	None	2	93	106

10	RRMS	51 – 60	F	Ocrelizumab	None	2	182	196
11	PPMS	41 – 50	F	Rituximab	None	3	98	306
12	RRMS	51 - 60	M	Rituximab	None	3	92	468

## Longitudinal PBMC samples of MS and MG patients during BCDT in the validation cohort

Cryopreserved longitudinal PBMC samples of MS and MG patients before and after BCDT in the validation cohort were collected at the Department of Neurology at Karolinska University Hospital (Table 2, Table 3). MS patients were diagnosed according to the revised McDonald criteria(79). The MG diagnosis was confirmed by at least 2 of the following: a positive AChR antibody test result, an abnormal electrophysiological test result (repetitive nerve stimulation and/or single fiber electromyography) consistent with MG, and/or a clinically significant response to an oral or intravenous AChEI test (per treating physician's opinion). All patients had given written informed consent and the study has been approved by the regional ethical review board of Stockholm (MS dnr. 2009/2107-21/2, last amendment dnr. 2022-03650-02; MG 2016-827-31).

In the validation cohort each patient had one timepoint before treatment and one timepoint after treatment. Inclusion criteria for the validation cohort included appropriate B cell depletion after BCDTs.

**Table 2:** Clinical and demographic characteristics of MS patients in the validation cohort.

ID	Diagnosis	Age Range	Sex	Treatment	Previous Treatment	Cycle of Treatment	Days Since Last Treatment	Days Since First Treatment
1	RRMS	21 – 30	M	Rituximab	None	1	185	185
2	RRMS	31 – 40	F	Rituximab	None	1	182	182
3	RRMS	21 - 30	F	Rituximab	None	3	112	475
4	RRMS	41 – 50	F	Rituximab	Cortisone	3	91	455
5	RRMS	21 – 30	F	Rituximab	Cortisone	2	188	360
6	RRMS	21 – 30	F	Rituximab	None	3	171	534
7	RRMS	21 – 30	F	Rituximab	None	3	108	468
8	RRMS	31 – 40	F	Rituximab	None	2	234	463
9	RRMS	41 – 50	M	Rituximab	None	6	126	1050
10	RRMS	31 – 40	M	Rituximab	None	6	12	925
11	RRMS	51 – 60	M	Rituximab	None	5	127	851
12	RRMS	51 – 60	F	Rituximab	None	2	27	207
13	RRMS	41 – 50	M	Rituximab	None	1	130	130
14	RRMS	31 - 40	M	Rituximab	Cortisone	1	90	90

**Table 3:** Clinical and demographic characteristics of MG patients in the validation cohort.

ID	Serology	Age Range	Sex	Treatment	Previous Treatment	Cycle of Treatment	Days Since Last Treatment	Days Since First Treatment
15	LRP4	61 - 70	M	Rituximab	None	1	197	197
16	AChR	41 – 50	M	Rituximab	Mestinon	1	215	215
17	LRP4	51 – 60	M	Rituximab	Cortisone, Mestinon	1	159	159
18	AChR	21 – 30	F	Rituximab	None	1	91	91
19	AChR	41 – 50	F	Rituximab	None	1	91	91
20	Negative	51 – 60	M	Rituximab	None	1	115	115
21	Negative	41 – 50	F	Rituximab	None	1	226	226
22	AChR	71 - 80	M	Rituximab	None	1	244	244

### Statistical analysis

322

323

329

333334

339

340

- 324 All statistical analyses were done in R. Wilcoxon effect size calculations were done with the R
- package "rstatix" and were used in the analysis of marker changes in the replenished B cell
- compartment. Non-parametric paired Wilcoxon rank-sum test from the R package "stats" was used
- 327 to compare two groups unless stated otherwise. Controlling for multiple comparisons was
- accomplished with the Benjamini-Hochberg approach also from the "stats" package.

## Study approval

- All donors had given written informed consent and the study was approved by the regional ethical
- 331 review board of Stockholm (MS dnr. 2009/2107-21/2, last amendment dnr. 2022-03650-02; MG
- 332 2016-827-31) and Basel (Ref.Nr. EK: 49/06), respectively.

#### SUPPLEMENTARY MATERIALS

- 335 Materials and Methods
- 336 Figs. S1 and S2
- Tables S1 to S3
- 338 References (80–86)

#### **References and Notes:**

- 1. A. Bar-Or, The Immunology of Multiple Sclerosis. Semin Neurol 28, 029–045 (2008).
- 2. C. A. Dendrou, L. Fugger, M. A. Friese, Immunopathology of multiple sclerosis. Nat Rev Immunol 15, 545–558
   (2015).
- 3. B. W. van Oosten, M. Lai, S. Hodgkinson, F. Barkhof, D. H. Miller, I. F. Moseley, A. J. Thompson, P. Rudge, A.
- McDougall, J. G. McLeod, H. J. Ader, C. H. Polman, Treatment of multiple sclerosis with the monoclonal anti-CD4
- antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial.
- 347 Neurology 49, 351–357 (1997).
- 4. J. M. Gelfand, B. A. C. Cree, S. L. Hauser, Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in
- 349 Multiple Sclerosis. Neurotherapeutics 14, 835–841 (2017).

- 5. R. Li, K. R. Patterson, A. Bar-Or, Reassessing B cell contributions in multiple sclerosis. Nat Immunol 19, 696–
- 351 707 (2018).
- 6. S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S.
- Agarwal, A. Langer-Gould, C. H. Smith, B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple
- 354 Sclerosis. New England Journal of Medicine 358, 676–688 (2008).
- 7. G. Comi, A. Bar-Or, H. Lassmann, A. Uccelli, H. Hartung, X. Montalban, P. S. Sørensen, R. Hohlfeld, S. L.
- Hauser, Role of B Cells in Multiple Sclerosis and Related Disorders. Ann Neurol 89, 13–23 (2021).
- 8. D. S. W. Lee, O. L. Rojas, J. L. Gommerman, B cell depletion therapies in autoimmune disease: advances and
- mechanistic insights. Nat Rev Drug Discov 20, 179–199 (2021).
- 9. P. A. Gordon, D. J. Carroll, W. S. Etches, V. Jeffrey, L. Marsh, B. L. Morrice, D. Olmstead, K. G. Warren, A
- Double-blind Controlled Pilot Study of Plasma Exchange versus Sham Apheresis in Chronic Progressive Multiple
- Sclerosis. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 12, 39–44 (1985).
- 10. B. G. Weinshenker, P. C. O'Brien, T. M. Petterson, J. H. Noseworthy, C. F. Lucchinetti, D. W. Dodick, A. A.
- Pineda, L. N. Stevens, M. Rodriguez, A randomized trial of plasma exchange in acute central nervous system
- inflammatory demyelinating disease. Ann Neurol 46, 878–886 (1999).
- 366 11. D. Pöhlau, H. Przuntek, M. Sailer, F. Bethke, J. Koehler, N. König, C. Heesen, P. Späth, I. Andresen,
- Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo
- 368 controlled multicentre study. Multiple Sclerosis Journal 13, 1107–1117 (2007).
- 369 12. F. Fazekas, F. D. Lublin, D. Li, M. S. Freedman, H. P. Hartung, P. Rieckmann, P. S. Sorensen, M. Maas-
- Enriquez, B. Sommerauer, K. Hanna, Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: A dose-finding trial. Neurology 71, 265–271 (2008).
- 372 13. F. Fazekas, P. S. Sørensen, M. Filippi, S. Ropele, X. Lin, H. W. Koelmel, O. Fernandez, C. Pozzilli, P.
- O'Connor, M. M. Enriquez, O. R. Hommes, MRI results from the European Study on Intravenous Immunoglobulin
- in Secondary Progressive Multiple Sclerosis (ESIMS). Multiple Sclerosis Journal 11, 433–440 (2005).
- 14. M. Duddy, M. Niino, F. Adatia, S. Hebert, M. Freedman, H. Atkins, H. J. Kim, A. Bar-Or, Distinct Effector
- Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis. The Journal of Immunology 178, 6092–6099 (2007).
- 378 15. A. Bar-Or, L. Fawaz, B. Fan, P. J. Darlington, A. Rieger, C. Ghorayeb, P. A. Calabresi, E. Waubant, S. L.
- Hauser, J. Zhang, C. H. Smith, Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 67, 452–461 (2010).
- 381 16. T. A. Barr, P. Shen, S. Brown, V. Lampropoulou, T. Roch, S. Lawrie, B. Fan, R. A. O'Connor, S. M. Anderton,
- A. Bar-Or, S. Fillatreau, D. Gray, B cell depletion therapy ameliorates autoimmune disease through ablation of IL-
- 6-producing B cells. Journal of Experimental Medicine 209, 1001–1010 (2012).
- 17. C. Blanco-Jerez, J. F. Plaza, J. Masjuan, L. M. Orensanz, J. C. Álvarez-Cermeño, Increased levels of IL-15
- 385 mRNA in relapsing–remitting multiple sclerosis attacks. J Neuroimmunol 128, 90–94 (2002).
- 18. M. Rentzos, C. Cambouri, A. Rombos, C. Nikolaou, M. Anagnostouli, A. Tsoutsou, A. Dimitrakopoulos, N.
- 387 Triantafyllou, D. Vassilopoulos, IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple
- 388 sclerosis. J Neurol Sci 241, 25–29 (2006).
- 389 19. R. Li, A. Rezk, Y. Miyazaki, E. Hilgenberg, H. Touil, P. Shen, C. S. Moore, L. Michel, F. Althekair, S.
- 390 Rajasekharan, J. L. Gommerman, A. Prat, S. Fillatreau, A. Bar-Or, Proinflammatory GM-CSF-producing B cells in
- multiple sclerosis and B cell depletion therapy. Sci Transl Med 7 (2015), doi:10.1126/scitranslmed.aab4176.
- 392 20. Y. Miyazaki, R. Li, A. Rezk, H. Misirliyan, C. Moore, N. Farooqi, M. Solis, L. G. Goiry, O. de Faria Junior, V.
- D. Dang, D. Colman, A. S. Dhaunchak, J. Antel, J. Gommerman, A. Prat, S. Fillatreau, A. Bar-Or, M. S. Horwitz,
- 394 Ed. A Novel MicroRNA-132-Surtuin-1 Axis Underlies Aberrant B-cell Cytokine Regulation in Patients with
- Relapsing-Remitting Multiple Sclerosis. PLoS One 9, e105421 (2014).
- 396 21, D. Ghosh, W. Jiang, D. Mukhopadhyay, E. D. Mellins, New insights into B cells as antigen presenting cells.
- 397 Curr Opin Immunol 70, 129–137 (2021).
- 398 22. M. R. Lincoln, A. Montpetit, M. Z. Cader, J. Saarela, D. A. Dyment, M. Tiislar, V. Ferretti, P. J. Tienari, A. D.
- 399 Sadovnick, L. Peltonen, G. C. Ebers, T. J. Hudson, A predominant role for the HLA class II region in the association
- of the MHC region with multiple sclerosis. Nat Genet 37, 1108–1112 (2005).
- 401 23. O. Olerup, J. Hillert, HLA class II-associated genetic susceptibility in multiple sclerosis: A critical evaluation.
- 402 Tissue Antigens 38, 1–15 (1991).
- 403 24. A. Spurkland, K. Skjold Rønningen, B. Vandvik, E. Thorsby, F. Vartdal, HLA-DQA1 and HLA-DQB1 genes
- 404 may jointly determine susceptibility to develop multiple sclerosis. Hum Immunol 30, 69–75 (1991).

- 405 25. C. Jersild, G. Hansen, A. Svejgaard, T. Fog, M. Thomsen, B. Dupont, HISTOCOMPATIBILITY
- 406 DETERMINANTS IN MULTIPLE SCLEROSIS, WITH SPECIAL REFERENCE TO CLINICAL COURSE. The
- 407 Lancet 302, 1221–1225 (1973).
- 408 26. D. G. Maloney, A. J. Grillo-López, D. J. Bodkin, C. A. White, T. M. Liles, I. Royston, C. Varns, J. Rosenberg,
- 409 R. Levy, IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
- 410 Journal of Clinical Oncology 15, 3266–3274 (1997).
- 411 27. A. Bar-Or, P. A. J. Calabresi, D. Arnold, C. Markowitz, S. Shafer, L. H. Kasper, E. Waubant, S. Gazda, R. J.
- 412 Fox, M. Panzara, N. Sarkar, S. Agarwal, C. H. Smith, Rituximab in relapsing-remitting multiple sclerosis: A 72-
- 413 week, open-label, phase I trial. Ann Neurol 63, 395–400 (2008).
- 28. T. Okada, V. N. Ngo, E. H. Ekland, R. Förster, M. Lipp, D. R. Littman, J. G. Cyster, Chemokine Requirements
- for B Cell Entry to Lymph Nodes and Peyer's Patches. Journal of Experimental Medicine 196, 65–75 (2002).
- 416 29. S. J. Rodig, A. Shahsafaei, B. Li, C. R. Mackay, D. M. Dorfman, BAFF-R, the major B cell-activating factor
- receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol 36, 1113–1119 (2005).
- 30. L. Kappos, H.-P. Hartung, M. S. Freedman, A. Boyko, E. W. Radü, D. D. Mikol, M. Lamarine, Y. Hyvert, U.
- Freudensprung, T. Plitz, J. van Beek, Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled,
- double-blind, phase 2 trial. Lancet Neurol 13, 353–363 (2014).
- 422 31. N. D. Huntington, R. Tomioka, C. Clavarino, A. M. Chow, D. Liñares, P. Maña, J. Rossjohn, T. G. Cachero, F.
- 423 Qian, S. L. Kalled, C. C. A. Bernard, H. H. Reid, A BAFF antagonist suppresses experimental autoimmune
- 424 encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol 18, 1473–85 (2006).
- 425 32. X. Zhou, Z. Xia, Q. Lan, J. Wang, W. Su, Y.-P. Han, H. Fan, Z. Liu, W. Stohl, S. G. Zheng, A. Zernecke, Ed.
- 426 BAFF Promotes Th17 Cells and Aggravates Experimental Autoimmune Encephalomyelitis. PLoS One 6, e23629 427 (2011).
- 428 33. A. Cherukuri, P. C. Cheng, H. W. Sohn, S. K. Pierce, The CD19/CD21 Complex Functions to Prolong B Cell
- Antigen Receptor Signaling from Lipid Rafts. Immunity 14, 169–179 (2001).
- 430 34. M. W. J. Wentink, M. C. van Zelm, J. J. M. van Dongen, K. Warnatz, M. van der Burg, Deficiencies in the
- 431 CD19 complex. Clinical Immunology 195, 82–87 (2018).
- 432 35. J. van Langelaar, L. Rijvers, J. Smolders, M. M. van Luijn, B and T Cells Driving Multiple Sclerosis: Identity,
- 433 Mechanisms and Potential Triggers. Front Immunol 11 (2020), doi:10.3389/fimmu.2020.00760.
- 434 36. X. Fan, T. Jin, S. Zhao, C. Liu, J. Han, X. Jiang, Y. Jiang, N. Fazilleau, Ed. Circulating CCR7+ICOS+ Memory
- T Follicular Helper Cells in Patients with Multiple Sclerosis. PLoS One 10, e0134523 (2015).
- 436 37. J. Guo, C. Zhao, F. Wu, L. Tao, C. Zhang, D. Zhao, S. Yang, D. Jiang, J. Wang, Y. Sun, Z. Li, H. Li, K. Yang, T
- 437 Follicular Helper-Like Cells Are Involved in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
- 438 Front Immunol 9 (2018), doi:10.3389/fimmu.2018.00944.
- 439 38. A. E. Lovett-Racke, M. Gormley, Y. Liu, Y. Yang, C. Graham, S. Wray, M. K. Racke, R. Shubin, C. Twyman,
- E. Alvarez, A. Bass, J. L. Eubanks, E. Fox, B cell depletion with ublituximab reshapes the T cell profile in multiple
- sclerosis patients. J Neuroimmunol 332, 187–197 (2019).
- 39. E. S. Huseby, P. G. Huseby, S. Shah, R. Smith, B. D. Stadinski, Pathogenic CD8 T Cells in Multiple Sclerosis
- and Its Experimental Models. Front Immunol 3 (2012), doi:10.3389/fimmu.2012.00064.
- 444 40. H. Babbe, A. Roers, A. Waisman, H. Lassmann, N. Goebels, R. Hohlfeld, M. Friese, R. Schröder, M. Deckert, S.
- 445 Schmidt, R. Ravid, K. Rajewsky, Clonal Expansions of CD8+ T Cells Dominate the T Cell Infiltrate in Active
- 446 Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction. Journal of
- 447 Experimental Medicine 192, 393–404 (2000).
- 448 41. M. Salou, A. Garcia, L. Michel, A. Gainche-Salmon, D. Loussouarn, B. Nicol, F. Guillot, P. Hulin, S. Nedellec,
- D. Baron, G. Ramstein, J. Soulillou, S. Brouard, A. B. Nicot, N. Degauque, D. A. Laplaud, Expanded CD8 T-cell
- sharing between periphery and CNS in multiple sclerosis. Ann Clin Transl Neurol 2, 609–622 (2015).
- 451 42. R. Q. Hintzen, RenéA. W. van Lier, K. C. Kuijpers, P. A. Baars, W. Schaasberg, C. J. Lucas, C. H. Polman,
- Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis
- 453 patients. J Neuroimmunol 35, 211–217 (1991).
- 43. M. Komori, A. Blake, M. Greenwood, Y. C. Lin, P. Kosa, D. Ghazali, P. Winokur, M. Natrajan, S. C. Wuest, E.
- 455 Romm, A. A. Panackal, P. R. Williamson, T. Wu, B. Bielekova, Cerebrospinal fluid markers reveal intrathecal
- inflammation in progressive multiple sclerosis. Ann Neurol 78, 3–20 (2015).
- 44. Y. Y. M. Wong, R. M. van der Vuurst de Vries, E. D. van Pelt, I. A. Ketelslegers, M.-J. Melief, A. F. Wierenga,
- 458 C. E. Catsman-Berrevoets, R. F. Neuteboom, R. Q. Hintzen, T-cell activation marker sCD27 is associated with
- 459 clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes. Multiple Sclerosis Journal 24,
- 460 1715–1724 (2018).

- 461 45. K. Agematsu, S. Hokibara, H. Nagumo, A. Komiyama, CD27: a memory B-cell marker. Immunol Today 21,
- 462 204–206 (2000).
- 46. B. K. Han, N. J. Olsen, A. Bottaro, The CD27-CD70 pathway and pathogenesis of autoimmune disease. Semin
- 464 Arthritis Rheum 45, 496–501 (2016).
- 465 47. S. M. A. Lens, K. Tesselaar, M. H. J. van Oers, R. A. W. van Lier, Control of lymphocyte function through
- 466 CD27–CD70 interactions. Semin Immunol 10, 491–499 (1998).
- 467 48. M. A. Nolte, R. W. van Olffen, K. P. J. M. van Gisbergen, R. A. W. van Lier, Timing and tuning of CD27-CD70
- 468 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology.
- 469 Immunol Rev 229, 216–231 (2009).
- 470 49. D. v Dolfi, A. C. Boesteanu, C. Petrovas, D. Xia, E. A. Butz, P. D. Katsikis, Late signals from CD27 prevent
- 471 Fas-dependent apoptosis of primary CD8+ T cells. Journal of immunology 180, 2912–21 (2008).
- 472 50. V. Peperzak, E. A. M. Veraar, A. M. Keller, Y. Xiao, J. Borst, The Pim Kinase Pathway Contributes to Survival
- 473 Signaling in Primed CD8+ T Cells upon CD27 Costimulation. The Journal of Immunology 185, 6670–6678 (2010).
- 51. J. Hendriks, L. A. Gravestein, K. Tesselaar, R. A. W. van Lier, T. N. M. Schumacher, J. Borst, CD27 is required
- for generation and long-term maintenance of T cell immunity. Nat Immunol 1, 433–440 (2000).
- 476 52. J. Hendriks, Y. Xiao, J. Borst, CD27 Promotes Survival of Activated T Cells and Complements CD28 in
- Generation and Establishment of the Effector T Cell Pool. Journal of Experimental Medicine 198, 1369–1380 (2003).
- 53. R. Q. Hintzen, S. M. Lens, K. Lammers, H. Kuiper, M. P. Beckmann, R. A. van Lier, Engagement of CD27 with
- its ligand CD70 provides a second signal for T cell activation. Journal of immunology 154, 2612–23 (1995).
- 481 54. H. Oshima, Characterization of murine CD70 by molecular cloning and mAb. Int Immunol 10, 517–526 (1998).
- 482 55. L. A. Gravestein, J. D. Nieland, A. M. Kruisbeek, J. Borst, Novel mAbs reveal potent co-stimulatory activity of
- 483 murine CD27. Int Immunol 7, 551–557 (1995).
- 484 56. R. Q. Hintzen, R. de Jong, S. M. A. Lens, RenéA. W. van Lier, CD27: marker and mediator of T-cell activation?
- 485 Immunol Today 15, 307–311 (1994).
- 486 57. R. A. van Lier, J. Borst, T. M. Vroom, H. Klein, P. van Mourik, W. P. Zeijlemaker, C. J. Melief, Tissue
- distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen.
- 488 Journal of immunology 139, 1589–96 (1987).
- 489 58. K. Kato, P. Chu, S. Takahashi, H. Hamada, T. J. Kipps, Metalloprotease inhibitors block release of soluble
- 490 CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Exp Hematol 35, 434–491 442 (2007).
- 492 59. W. A. M. Loenen, E. de Vries, L. A. Gravestein, R. Q. Hintzen, R. A. W. van Lier, J. Borst, The CD27
- 493 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a
- soluble form by protein processing that does not involve receptor endocytosis. Eur J Immunol 22, 447–455 (1992).
- 495 60. F. Piehl, A. Eriksson-Dufva, A. Budzianowska, A. Feresiadou, W. Hansson, M. A. Hietala, I. Håkansson, R.
- 496 Johansson, D. Jons, I. Kmezic, C. Lindberg, J. Lindh, F. Lundin, I. Nygren, A. R. Punga, R. Press, K. Samuelsson,
- 497 P. Sundström, O. Wickberg, S. Brauner, T. Frisell, Efficacy and Safety of Rituximab for New-Onset Generalized
- 498 Myasthenia Gravis. JAMA Neurol (2022), doi:10.1001/jamaneurol.2022.2887.
- 499 61. R. J. Nowak, C. S. Coffey, J. M. Goldstein, M. M. Dimachkie, M. Benatar, J. T. Kissel, G. I. Wolfe, T. M.
- 500 Burns, M. L. Freimer, S. Nations, V. Granit, A. G. Smith, D. P. Richman, E. Ciafaloni, M. T. Al-Lozi, L. A. Sams,
- D. Quan, E. Ubogu, B. Pearson, A. Sharma, J. W. Yankey, L. Uribe, M. Shy, A. A. Amato, R. Conwit, K. C.
- 502 O'Connor, D. A. Hafler, M. E. Cudkowicz, R. J. Barohn, Phase 2 Trial of Rituximab in Acetylcholine Receptor
- 503 Antibody-Positive Generalized Myasthenia Gravis. Neurology 98, e376–e389 (2022).
- 62. D. Hamann, P. A. Baars, M. H. G. Rep, B. Hooibrink, S. R. Kerkhof-Garde, M. R. Klein, R. A. W. van Lier,
- 505 Phenotypic and Functional Separation of Memory and Effector Human CD8+ T Cells. Journal of Experimental
- 506 Medicine 186, 1407–1418 (1997).
- 507 63, R. M. van der Vuurst de Vries, J. Y. Mescheriakova, T. F. Runia, N. Jafari, T. A. M. Siepman, R. O. Hintzen,
- 508 Soluble CD27 Levels in Cerebrospinal Fluid as a Prognostic Biomarker in Clinically Isolated Syndrome. JAMA
- 509 Neurol 74, 286 (2017).
- 510 64. M. Komori, Y. C. Lin, I. Cortese, A. Blake, J. Ohayon, J. Cherup, D. Maric, P. Kosa, T. Wu, B. Bielekova,
- Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol 3,
- 512 166–179 (2016).
- 513 65. J. Romme Christensen, M. Komori, M. R. von Essen, R. Ratzer, L. Börnsen, B. Bielekova, F. Sellebjerg, CSF
- 514 inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation
- associated with axonal damage. Multiple Sclerosis Journal 25, 937–946 (2019).

- 516 66. M. R. Mahler, H. B. Søndergaard, S. Buhelt, M. R. von Essen, J. Romme Christensen, C. Enevold, F. Sellebjerg,
- 517 Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis. Mult Scler Relat Disord 45, 102391
- 518 (2020)
- 519 67. A. Nakajima, H. Oshima, C. Nohara, S. Morimoto, S. Yoshino, T. Kobata, H. Yagita, K. Okumura, Involvement
- of CD70–CD27 interactions in the induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 109,
- 521 188–196 (2000).
- 522 68. S. Yanagisawa, N. Takeichi, T. Kaneyama, H. Yagita, S. Taniguchi, B. S. Kim, C.-S. Koh, Effects of anti-CD70
- mAb on Theiler's murine encephalomyelitis virus-induced demyelinaiting disease. Brain Res 1317, 236–245 (2010).
- 69. G. FrancoSalinas, T. Cantaert, M. A. Nolte, P. P. Tak, R. A. W. van Lier, D. L. Baeten, Enhanced costimulation
- 525 by CD70+ B cells aggravates experimental autoimmune encephalomyelitis in autoimmune mice. J Neuroimmunol
- 526 255, 8–17 (2013).
- 527 70. X. Zhang, R. Ge, H. Chen, M. Ahiafor, B. Liu, J. Chen, X. Fan, J. O. Martins, Ed. Follicular Helper CD4+ T
- 528 Cells, Follicular Regulatory CD4+ T Cells, and Inducible Costimulator and Their Roles in Multiple Sclerosis and
- 529 Experimental Autoimmune Encephalomyelitis. Mediators Inflamm 2021, 1–10 (2021).
- 71. D. F. Legler, M. Loetscher, R. S. Roos, I. Clark-Lewis, M. Baggiolini, B. Moser, B Cell-attracting Chemokine
- 531 1, a Human CXC Chemokine Expressed in Lymphoid Tissues, Selectively Attracts B Lymphocytes via
- 532 BLR1/CXCR5. Journal of Experimental Medicine 187, 655–660 (1998).
- 533 72. L. M. Ebert, P. Schaerli, B. Moser, Chemokine-mediated control of T cell traffic in lymphoid and peripheral
- tissues. Mol Immunol 42, 799–809 (2005).
- 535 73. F. Sellebjerg, L. Bornsen, M. Khademi, M. Krakauer, T. Olsson, J. L. Frederiksen, P. S. Sorensen, Increased
- cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 73, 2003–2010 (2009).
- 537 74. M. Khademi, I. Kockum, M. L. Andersson, E. Iacobaeus, L. Brundin, F. Sellebjerg, J. Hillert, F. Piehl, T.
- Olsson, Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.
- 539 Multiple Sclerosis Journal 17, 335–343 (2011).
- 540 75. L. Piccio, R. T. Naismith, K. Trinkaus, R. S. Klein, B. J. Parks, J. A. Lyons, A. H. Cross, Changes in B- and T-
- Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis. Arch Neurol 67, 707–714
- 542 (2010).
- 543 76. A. Corcione, S. Casazza, E. Ferretti, D. Giunti, E. Zappia, A. Pistorio, C. Gambini, G. L. Mancardi, A. Uccelli,
- V. Pistoia, Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis.
- Proceedings of the National Academy of Sciences 101, 11064–11069 (2004).
- 546 77. M. Krumbholz, D. Theil, S. Cepok, B. Hemmer, P. Kivisäkk, R. M. Ransohoff, M. Hofbauer, C. Farina, T.
- Derfuss, C. Hartle, J. Newcombe, R. Hohlfeld, E. Meinl, Chemokines in multiple sclerosis: CXCL12 and CXCL13
- 548 up-regulation is differentially linked to CNS immune cell recruitment. Brain 129, 200–211 (2006).
- 78. N. Schmitt, Role of T Follicular Helper cells in Multiple Sclerosis. J Nat Sci 1, e139 (2015).
- 550 79. A. J. Thompson, B. L. Banwell, F. Barkhof, W. M. Carroll, T. Coetzee, G. Comi, J. Correale, F. Fazekas, M.
- 551 Filippi, M. S. Freedman, K. Fujihara, S. L. Galetta, H. P. Hartung, L. Kappos, F. D. Lublin, R. A. Marrie, A. E.
- Miller, D. H. Miller, X. Montalban, E. M. Mowry, P. S. Sorensen, M. Tintoré, A. L. Traboulsee, M. Trojano, B. M.
- J. Uitdehaag, S. Vukusic, E. Waubant, B. G. Weinshenker, S. C. Reingold, J. A. Cohen, Diagnosis of multiple
- sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17, 162–173 (2018).
- 80. F. Ingelfinger, S. Krishnarajah, M. Kramer, S. G. Utz, E. Galli, M. Lutz, P. Zwicky, A. U. Akarca, N. P. Jurado,
- 556 C. Ulutekin, D. Bamert, C. C. Widmer, L. Piccoli, F. Sallusto, N. G. Núñez, T. Marafioti, D. Schneiter, I. Opitz, A.
- Lanzavecchia, H. H. Jung, D. de Feo, S. Mundt, B. Schreiner, B. Becher, Single-cell profiling of myasthenia gravis
- identifies a pathogenic T cell signature. Acta Neuropathol 141, 901–915 (2021).
- 559 81. F. Ingelfinger, L. A. Gerdes, V. Kavaka, S. Krishnarajah, E. Friebel, E. Galli, P. Zwicky, R. Furrer, C. Peukert,
- 560 C.-A. Dutertre, K. M. Eglseer, F. Ginhoux, A. Flierl-Hecht, T. Kümpfel, D. de Feo, B. Schreiner, S. Mundt, M.
- Kerschensteiner, R. Hohlfeld, E. Beltrán, B. Becher, Twin study reveals non-heritable immune perturbations in
- 562 multiple sclerosis. Nature 603, 152–158 (2022).
- 563 82. R. Finck, E. F. Simonds, A. Jager, S. Krishnaswamy, K. Sachs, W. Fantl, D. Pe'er, G. P. Nolan, S. C. Bendall,
- Normalization of mass cytometry data with bead standards. Cytometry Part A 83A, 483–494 (2013).
- 565 83. S. van Gassen, B. Gaudilliere, M. S. Angst, Y. Saeys, N. Aghaeepour, CytoNorm: A Normalization Algorithm
- 566 for Cytometry Data. Cytometry Part A 97, 268–278 (2020).
- 84. S. van Gassen, B. Callebaut, M. J. van Helden, B. N. Lambrecht, P. Demeester, T. Dhaene, Y. Saeys, FlowSOM:
- 568 Using self-organizing maps for visualization and interpretation of cytometry data. Cytometry Part A 87, 636–645
- 569 (2015)
- 85. M. D. Wilkerson, D. N. Hayes, ConsensusClusterPlus: a class discovery tool with confidence assessments and
- item tracking. Bioinformatics 26, 1572–1573 (2010).

- 86. L. McInnes, J. Healy, N. Saul, L. Großberger, UMAP: Uniform Manifold Approximation and Projection. J Open
- 573 Source Softw 3, 861 (2018).

574

- Acknowledgments: We thank all the patients that participated in the study. We thank Catarina
- Raposo for the helpful review of the manuscript.
- Funding: This work received project funding from Roche Pharma (to B.B.) and from the European
- Research Council (ERC) under the European Union's Horizon 2020 research and innovation
- program grant agreement no. 882424 (to B.B.), the Swiss National Science Foundation (733
- 580 310030 170320, 310030 188450 and CRSII5 183478 to B.B.), as well as the Swiss MS Society
- Research grant (to F.I.); F.I. received a PhD fellowship from the Studienstiftung des deutschen
- Volkes. T.O. has grant support from the Swedish Research council, the Knut and Alice Wallenberg
- foundation, the Swedish Brain Foundation and Margaretha af Ugglas Foundation.
- Author contributions: E.G. and F.I. generated the mass cytometry data. C.U. analyzed all the
- data. I.C., M.K., F.P., N.S., R.F., T.O. and T.D. performed clinical characterization of the cohorts
- and provided patient samples and clinical input. B.B. and F.I. jointly supervised the study. B.B.
- funded the study. C.U., F.I. and B.B. wrote the manuscript.
- Competing interests: This study was partially funded by Roche Pharma. T.O. has received
- advisory board/lecture honoraria and unrestricted MS research grants from Biogen, Sanofi, Merck,
- and Novartis, none of which has any relation to the current study. Other than that, the authors
- declare no conflict of interest.
- Data and materials availability: Mass cytometry data of the discovery and validation cohort will
- be made publicly available upon publication. Custom analysis code to reproduce the analysis will
- be uploaded to a public repository.